BioPharm International-01-01-2013

Burrill on Biotech

January 01, 2013

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

FDA talks about the changing scope of regulatory science.

Features

January 01, 2013

Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace.

From the Editor

January 01, 2013

Our editorial advisory board members provide their perspective on what's ahead in the biopharmaceutical industry.

Shortages spur efforts to overhaul manufacturing oversight.

The EU fine-tunes the Falsified Medicines Directive.

Features

January 01, 2013

What the industry's future holds and what needs to be done to get there.

Global Reports

January 01, 2013

Brazil to locally produce HIV/AIDS antiretroviral drug atazanavir.

Features

January 01, 2013

NIBRT's Ray O'Connor provides an overview of aseptic processing.

Features

January 01, 2013

Neil Lewis, chief technology officer at Malvern Instruments, talks about the challenges associated with biologics.

A new downstream purification platform using a salt-tolerant membrane adsorber.

Online Exclusive

January 01, 2013

A recent ISPE guidance provides a baseline for the design of quality laboratory facilities.

Conjugation of a biologic to a carrier molecule can solve problems in solubility and stability, but introduces its own challenges.

Perspectives on Outsourcing

January 01, 2013

Will international biomanufacturing outsourcing become mainstream in this decade?

The Future of BioPharma Innovation